BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 2.95M
Average 4.85M
BCRX Total Liabilities
Everything the company owes to creditors and other parties.
BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 15.2% from a year ago
Total liabilities stood at $1.01B at the end of Q2 FY2026, up 15.2% from a year earlier and down 0.7% from the prior quarter. Over 3 fiscal years it compounded at -9.2% a year.
Context
- Total liabilities amounted to 181.4% of total assets at the end of Q2 FY2026, down 10.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +15.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 633.31M USD
- Year-over-year change
- -34.5%
- 4-year CAGR
- -2.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 633.31M | -34.5% |
| FY2024 | 2024-12-31 | 966.35M | -0.6% |
| FY2023 | 2023-12-31 | 972.49M | +15.1% |
| FY2022 | 2022-12-31 | 844.6M | +21.5% |
| FY2021 | 2021-12-31 | 695.14M | — |
Total Liabilities vs competitors
How BCRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +15.2% is the 2nd highest of 4, against a peer median of +12.9%.
- Total liabilities amounts to 181.4% of total assets for BCRX, versus a peer median of 12.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.01B USD | +15.2% | -9.2% | 181.4% | |
| Mar 2026 | $212.82M USD | -19.4% | -31.0% | 20.8% | |
| Mar 2026 | $33.37M USD | +15.5% | +15.0% | 12.5% | |
| Sep 2026 | €30.09M EUR | +12.9% | +17.8% | 10.2% | |
| Peer median (excluding BCRX) | — | +12.9% | +15.0% | 12.5% | |
Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 504.39M | 304.77M | 110.64M | 104.92M | 89.74M |
| Short-term Investments | 3.21M | 119.54M | 278.34M | 216.14M | 185.01M |
| Net Receivables | 29.41M | 50.6M | 56.95M | 79.07M | 106.82M |
| Inventory | 15.79M | 27.53M | 28.68M | 8.09M | 5.4M |
| Other Current Assets | 3.35M | 14.06M | 21.35M | 13.75M | 17.38M |
| Total Current Assets | 566.14M | 516.5M | 495.97M | 421.97M | 404.35M |
| Property, Plant & Equipment (Net) | 15.19M | 8.62M | 20.91M | 19.79M | 18.99M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 6.83M | 18.08M | 0 | 21.72M | 61.16M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 6.81M | 80K | 26.94M | 29.66M |
| Total Non-current Assets | 22.02M | 33.5M | 20.99M | 68.45M | 109.81M |
| Total Assets | 588.15M | 550M | 516.96M | 490.42M | 514.16M |
| Account Payables | 27.81M | 14.36M | 20.89M | 11.64M | 15.83M |
| Short-term Debt | 0 | 0 | 0 | 35.45M | 0 |
| Tax Payables | 2.62M | 410K | 0 | 0 | 0 |
| Deferred Revenue | 1.42M | 1.22M | 0 | 0 | 0 |
| Other Current Liabilities | 52M | 36.46M | 86.59M | 64.66M | 129.69M |
| Total Current Liabilities | 103.72M | 105.51M | 149.99M | 160.38M | 196.07M |
| Long-term Debt | 585.46M | 733.28M | 811.27M | 795.92M | 427.23M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 591.42M | 739.08M | 822.5M | 805.97M | 437.25M |
| Total Liabilities | 695.14M | 844.6M | 972.49M | 966.35M | 633.31M |
| Common Stock | 1.84M | 1.88M | 2.06M | 2.09M | 2.13M |
| Retained Earnings | (1.21B) | (1.45B) | (1.68B) | (1.77B) | (1.51B) |
| Accumulated OCI | 177K | 26K | 1.34M | 921K | 38K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (106.99M) | (294.6M) | (455.53M) | (475.93M) | (119.15M) |
| Total Debt | 593.24M | 741.45M | 825.15M | 841.42M | 438.87M |
| Net Debt | 88.85M | 436.69M | 714.51M | 736.5M | 349.14M |
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Intrinsic Alpha fair value
Locked
Current Price
$7.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.